Skip to content

EVOKE PHARMA, INC.: 10-Q filed 2025-11-13

What EVOKE PHARMA, INC. reported in its quarterly report filed 2025-11-13 (fiscal Q3 2025): 30 published measures, 97 facts as tagged in accession 0001193125-25-278802.

This filing

Form
10-Q (quarterly report)
Filed
2025-11-13
Fiscal period
fiscal Q3 2025
Accession
0001193125-25-278802 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All EVOKE PHARMA, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-09-3015,649,433USD
At 2024-12-3117,519,007USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-09-3012,287,197USD
At 2024-12-3110,480,997USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-09-303,362,236USD
At 2025-06-304,374,492USD
At 2025-03-315,841,215USD
At 2024-12-317,038,010USD
At 2024-09-304,387,136USD
At 2024-06-302,664,958USD
At 2024-03-313,497,169USD
At 2023-12-31-2,579,537USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2025-09-3011,576,010USD
At 2024-12-3113,596,600USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-1,156,208USD92
2025-01-01 to 2025-09-30-4,033,362USD273
2025-04-01 to 2025-06-30-1,570,976USD91
2025-01-01 to 2025-03-31-1,306,178USD90
2024-07-01 to 2024-09-30-1,312,390USD92
2024-01-01 to 2024-09-30-4,159,428USD274
2024-04-01 to 2024-06-30-1,267,218USD91
2024-01-01 to 2024-03-31-1,579,820USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-01-01 to 2025-09-30-2,084,485USD273
2024-01-01 to 2024-09-30-4,218,700USD274

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2025-07-01 to 2025-09-304,283,979USD92
2025-01-01 to 2025-09-3011,116,279USD273
2024-07-01 to 2024-09-302,654,186USD92
2024-01-01 to 2024-09-306,941,042USD274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2025-01-01 to 2025-09-3063,895USD273
2024-01-01 to 2024-09-3010,818,306USD274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-09-30-132,824,994USD
At 2024-12-31-128,791,632USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2025-07-01 to 2025-09-302,557,408shares92
2025-01-01 to 2025-09-302,553,121shares273
2024-07-01 to 2024-09-301,399,882shares92
2024-01-01 to 2024-09-301,381,703shares274

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-07-01 to 2025-09-302,557,408shares92
2025-01-01 to 2025-09-302,553,121shares273
2024-07-01 to 2024-09-301,399,882shares92
2024-01-01 to 2024-09-301,381,703shares274

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-0.45USD/shares92
2025-01-01 to 2025-09-30-1.58USD/shares273
2024-07-01 to 2024-09-30-0.94USD/shares92
2024-01-01 to 2024-09-30-3.01USD/shares274

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-0.45USD/shares92
2025-01-01 to 2025-09-30-1.58USD/shares273
2024-07-01 to 2024-09-30-0.94USD/shares92
2024-01-01 to 2024-09-30-3.01USD/shares274

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2025-07-01 to 2025-09-30105,056USD92
2025-01-01 to 2025-09-30293,693USD273
2024-07-01 to 2024-09-30131,587USD92
2024-01-01 to 2024-09-30512,194USD274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-1,137,688USD92
2025-01-01 to 2025-09-30-3,998,283USD273
2024-07-01 to 2024-09-30-1,285,657USD92
2024-01-01 to 2024-09-30-4,010,439USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-09-3015,536,407USD
At 2024-12-3117,237,897USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2025-07-01 to 2025-09-30126,027USD92
2025-01-01 to 2025-09-30373,973USD273
2024-07-01 to 2024-09-30126,027USD92
2024-01-01 to 2024-09-30375,342USD274

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-09-3012,240,816USD
At 2024-12-3110,380,039USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2025-07-01 to 2025-09-305,421,667USD92
2025-01-01 to 2025-09-3015,114,562USD273
2024-07-01 to 2024-09-303,939,843USD92
2024-01-01 to 2024-09-3010,951,481USD274

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2025-09-30599,908USD
At 2024-12-31445,081USD

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2025-07-01 to 2025-09-305,314,370USD92
2025-01-01 to 2025-09-3014,746,777USD273
2024-07-01 to 2024-09-303,824,142USD92
2024-01-01 to 2024-09-3010,697,128USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-09-301,722,409shares
At 2024-12-311,486,009shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2025-09-3011,576,010USD
At 2024-12-3113,596,600USD
At 2024-09-3011,339,032USD
At 2023-12-314,739,426USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2025-09-30106,714USD
At 2024-12-31154,184USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2025-09-30112,349USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2025-09-306,312USD
At 2024-12-316,312USD

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-18,520USD92
2025-01-01 to 2025-09-30-35,079USD273
2024-07-01 to 2024-09-30-26,733USD92
2024-01-01 to 2024-09-30-148,989USD274

Operating lease payments

Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.

PeriodValueUnitDays
2025-07-01 to 2025-09-3019,371USD92
2025-01-01 to 2025-09-3058,113USD273
2024-07-01 to 2024-09-3018,982USD92
2024-01-01 to 2024-09-3056,884USD274

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2025-01-01 to 2025-09-30770,113USD273
2024-01-01 to 2024-09-301,349,447USD274

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2025-01-01 to 2025-09-30154,827USD273
2024-01-01 to 2024-09-3011,568USD274

Inspect the source

Entity
EVOKE PHARMA, INC. / CIK 0001403708
Captured
2026-09-21T17:19:23.305Z
SEC response SHA-256
1d2ea0edbbb48066d62d49983dacdd25cf55cdf81e3ee5a742e26303a1f7d06e

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001403708.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))